Biogen surges 47% on FDA support for Alzheimer’s drug
In an unusual move, the US Food and Drug Administration combines its reviewers’ findings with Biogen’s in one document ahead of meeting on the drug
04 November 2020 - 21:11
New York — Biogen’s experimental Alzheimer’s disease therapy appears effective despite conflicting clinical-trial results, according to a report by the US Food and Drug Administration (FDA), a positive sign that a drug the company once wrote off could gain approval.
Biogen shares gained as much as 47% Wednesday, the largest gain on record based on data reaching back to 1991. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.